Devonian Health Group Inc. focuses on developing botanical drugs, with its lead candidate Thykamine in phase 3 trials for treating atopic dermatitis. The company shows strong gross margins at 111.3%, indicating potential profitability, but faces significant concerns with negative EBITDA and net margins, reflecting ongoing losses. Its liquidity ratios are stable, but the low debt/equity ratio suggests minimal leverage. The high gross margin juxtaposed with poor overall financial performance raises questions about sustainable growth and profitability moving forward.
Loading financial metrics...
Company has $720K in cash but burned $2.9M last quarter. At this burn rate, only 0.2 quarters of runway remain without additional financing.
Revenue fell 81.9% year-over-year from $16.5M to $3.0M. The decline has persisted for multiple quarters.
Company posted a loss of $-6.1M over the last year, representing 204.1% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $11.8M over the last year.
Gross margin expanded by 30.7 percentage points, indicating improved pricing power or cost efficiency.
Exceptional gross margin of 67.9% indicates strong pricing power and competitive moat.
Fortress balance sheet: cash covers total debt 5.1×, providing significant financial flexibility.
Low debt-to-revenue ratio of 4.7% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q3 (April 30, 2026)